{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:10:35Z","timestamp":1789096235859,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>There is a rising prevalence of metabolic-associated steatotic liver disease (MASLD), particularly in patients with type 2 diabetes mellitus, which needs early detection and treatment to prevent the grave outcomes. Dapagliflozin and Saroglitazar are known to improve metabolic and liver health in patients with type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Our study was a randomised, controlled, open-label, parallel trial of 101 patients with T2DM and MASLD. Patients were randomly assigned to receive Dapagliflozin 10 mg or Saroglitazar 4 mg on top of standard diabetes care. The primary endpoints were changes in hepatic steatosis and fibrosis (FIB) as estimated by controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) using FibroScan, respectively. The secondary endpoints were changes in anthropometric parameters, glycemic parameters, lipid profiles, transaminases, and FIB scores, which were monitored at baseline, 3 months, and 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At the end of 6 months of study, both cohorts resulted in significant clinical benefits. Comparison between the two cohorts revealed no significant statistical difference between the two groups regarding their impact on the primary endpoints (CAP and LSM). Minimal but statistically significant intergroup differences were noted only for BMI (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.033) and LDL cholesterol (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.020) in the Dapagliflozin cohort and alanine transaminase levels (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.037) in the Saroglitazar cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Both Dapagliflozin and Saroglitazar are potent therapeutic options in patients with type 2 diabetes mellitus who also have MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_848_25","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:01:48Z","timestamp":1788195708000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.4103","volume":"30","author":[{"given":"Bijay K.","family":"Das","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayanidhi","family":"Meher","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourav","family":"Padhee","sequence":"additional","affiliation":[{"name":"Research and Development, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Sahu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devadarshini","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Prusty","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4103\/2230-8210.113758","article-title":"linicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?","volume":"17","author":"Kumar","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","article-title":"Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study","volume":"51","author":"Dasarathy","year":"2009","journal-title":"J Hepatol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/hep.23312","article-title":"Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.22429","article-title":"Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes","volume":"48","author":"Fracanzani","year":"2008","journal-title":"Hepatology"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: A prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"key":"R15-20260911","first-page":"e9065","article-title":"An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4 mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Mitra","year":"2020","journal-title":"Cureus"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience","volume":"7","author":"Chaudhuri","year":"2023","journal-title":"JGH Open"},{"key":"R17-20260911","first-page":"e14974","article-title":"Effect of dapagliflozin on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A single-center survey","volume":"13","author":"Das","year":"2021","journal-title":"Cureus"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: Multicentre, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"519","DOI":"10.18203\/2319-2003.ijbcp20251836","article-title":"Therapeutic outcome of Saroglitazar, a peroxisome proliferator activated receptor \u03b1\/\u03b3 agonist in diabetic and non-diabetic metabolic dysfunction associated steatotic liver disease","volume":"14","author":"Shah","year":"2025","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"(3)","key":"R20-20260911","first-page":"[5]","article-title":"Effect of saroglitazar on fibrosis-4 score in prediabetic patients with non-alcoholic fatty liver disease","volume":"17","author":"Binmazi","year":"2025","journal-title":"Int J Clin Pharmacol Res"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: Pooled analysis of phase I\u2013III clinical trials","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv Ther"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_848_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:01:05Z","timestamp":1789095665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_848_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_848_25","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}